IDEAYA Biosciences (IDYA) Free Cash Flow Growth (3y) (2021 - 2026)
Analysis
IDEAYA Biosciences (IDYA) Free Cash Flow Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -1.95% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -20.15% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 21.16% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 45.09% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 80.69% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -4.45% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 8.92% |
| 10 | IDEAYA Biosciences | 3.66 Bn | 2.83 Bn | - | -38.22% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -38.22% |
| Mar 31, 2026 | -38.75% |
| Dec 31, 2025 | -57.23% |
| Sep 30, 2025 | 96.84% |
| Jun 30, 2025 | -42.58% |
| Mar 31, 2025 | -45.08% |
| Dec 31, 2024 | -92.30% |
| Sep 30, 2024 | -56.65% |
| Jun 30, 2024 | -35.83% |
| Mar 31, 2024 | -45.26% |
| Dec 31, 2023 | -27.72% |
| Sep 30, 2023 | -32.79% |
| Jun 30, 2023 | -34.50% |
| Mar 31, 2023 | -43.98% |
| Dec 31, 2022 | -37.85% |
| Sep 30, 2022 | -33.45% |
| Jun 30, 2022 | -26.66% |
| Mar 31, 2022 | -24.80% |
| Dec 31, 2021 | -30.40% |
| Sep 30, 2021 | -10.07% |